Immunobiology of hepatocellular carcinoma

Langenbeck's Archives of Surgery

Volumn 397, Issue 5, 2012, Pages 673-680

  Flecken, Tobias ^a   Spangenberg, Hans Christian ^a   Thimme, Robert ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Hepatocellular carcinoma; NK cells; Regulatory T cells; T cells; Tumor immunology; Tumor immunopathogenesis; Tumor immunotherapy

Indexed keywords

ALPHA FETOPROTEIN; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINANT HUMAN NY ESO 1 PROTEIN; UNCLASSIFIED DRUG;

CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER RECURRENCE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEPATITIS B; HEPATITIS C; HEPATOMA CELL; HUMAN; IMMUNOBIOLOGY; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; METASTASIS POTENTIAL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TH17 CELL; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84863983544     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-011-0783-x     Document Type: Review

References (82)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348(17):1625-1638. doi:10.1056/NEJMoa021423
2. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533-543. doi:10.1016/S1470-2045(01)00486-7
3. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557-2576. doi:10.1053/j.gastro.2007.04.061
4. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl 1):S35-S50
5. Blum HE, Spangenberg HC (2007) Hepatocellular carcinoma: an update. Arch Iran Med 10(3):361-371
6. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6):1752-1763. doi:10.1053/j.gastro.2008.02.090
7. Spangenberg HC, Thimme R, Blum HE (2009) Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 6(7):423-432. doi:10.1038/nrgastro.2009.86
8. Breous E, Thimme R (2010) Potential of immunotherapy for hepatocellular carcinoma. J Hepatol. doi:10.1016/j.jhep.2010.10.013
9. Couzin-Frankel J (2010) Immune therapy steps up the attack. Science 330(6003):440-443. doi:10.1126/science.330.6003.440
10. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
11. Aravalli RN, Steer CJ, Cressman EN (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48(6):2047-2063. doi:10.1002/hep.22580
12. Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM (2009) Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 25(3):186-194. doi:10.1097/MOG.0b013e32832962a1
13. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, Park CK, Park SE, Kim SY, Lee SH, Park WS, Yoo NJ, Liu ET, Miller LD, Lee JY (2005) Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42(4):809-818. doi:10.1002/hep.20878
14. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, Ohgaki H (1999) Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 155(6):1795-1801
15. Cheng WT, Xu K, Tian DY, Zhang ZG, Liu LJ, Chen Y (2009) Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int J Oncol 34(3):829-836
16. Castello G, Scala S, Palmieri G, Curley SA, Izzo F (2010) HCVrelated hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol 134(3):237-250. doi:10.1016/j.clim.2009.10.007
17. Bartosch B, Thimme R, Blum HE, Zoulim F (2009) Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 51(4):810-820. doi:10.1016/j.jhep.2009.05.008
18. Moradpour D, Blum HE (2005) Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 17(5):477-483. doi:00042737-200505000-00002
19. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV (1998) Immune pathogenesis of hepatocellular carcinoma. J Exp Med 188(2):341-350
20. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancerrelated inflammation. Nature 454(7203):436-444. doi:10.1038/nature07205
21. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M (2009) A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16(4):295-308. doi:10.1016/j.ccr.2009.08.021
22. Barash H, RG E, Edrei Y, Ella E, Israel A, Cohen I, Corchia N, Ben-Moshe T, Pappo O, Pikarsky E, Goldenberg D, Shiloh Y, Galun E, Abramovitch R (2010) Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci USA 107(5):2207-2212. doi:10.1073/pnas.0908867107
23. French SW, Oliva J, French BA, Li J, Bardag-Gorce F (2010) Alcohol, nutrition and liver cancer: role of Toll-like receptor signaling. World J Gastroenterol 16(11):1344-1348
24. Heine H, Lien E (2003) Toll-like receptors and their function in innate and adaptive immunity. Int Arch Allergy Immunol 130(3):180-192. doi:10.1159/000069517IAA30180
25. Tanaka J, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Uchida K, Kojima T, Takei Y (2010) Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol 37(4):805-814
26. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q, Xiao YS, Xu YF (2010) Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol. doi:10.1016/j.jhep.2010.07.044
27. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR (2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32(8):1757-1762. doi:10.1007/s00268-008-9552-6
28. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L (2010) Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. doi:10.1016/j.jhep.2010.08.041
29. Yu JJ, Gaffen SL (2008) Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Front Biosci 13:170-177
30. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50(5):980-989. doi:10.1016/j.jhep.2008.12.033
31. Kuang DM, Peng C, Zhao Q, Wu Y, Zhu LY, Wang J, Yin XY, Li L, Zheng L (2010) Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol 185(3):1544-1549. doi:10.4049/jimmunol.0904094
32. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51(1):154-164. doi:10.1002/hep.23291
33. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M (1998) Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27(2):407-414. doi:10.1002/hep.510270214
34. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ (2006) Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 45(2):246-253. doi:10.1016/j.jhep.2005.12.027
35. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25(18):2586-2593. doi:10.1200/JCO.2006.09.4565
36. Hirano S, Iwashita Y, Sasaki A, Kai S, Ohta M, Kitano S (2007) Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes. J Gastroenterol Hepatol 22(5):690-696. doi:10.1111/j.1440-1746.2006.04551.x
37. Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A (2010) Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 52(3):370-379. doi:10.1016/j.jhep.2009.07.013
38. Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, Sakaki M, Doi H, Uozumi S, Omori R, Matsumura T, Yanagawa T, Ito T, Imawari M (2010) Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 45 (4):451-458. doi:10.1007/s00535-009-0155-2
39. Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G (2006) Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+ T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol 45(5):662-672. doi:10.1016/j.jhep.2006.05.018
40. Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461-469. doi:10.1182/blood-2007-09-077438
41. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K (1998) Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 83(1):58-63. doi:10.1002/(SICI) 1097-0142(19980701) 83:1<58::AID-CNCR8>3.0. CO;2-A
42. Chuang WL, Liu HW, Chang WY (1990) Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 65(4):926-930
43. Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, Jinushi M, Sugimoto Y, Sasaki Y, Hori M, Hayashi N (2003) CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 106(1):81-89. doi:10.1002/ijc.11163
44. Chen X, Fu S, Chen F, Chen H, Chen Z (2008) Identification of tumor-associated antigens in human hepatocellular carcinoma by autoantibodies. Oncol Rep 20(4):979-985
45. Heo CK, Woo MK, Yu DY, Lee JY, Yoo JS, Yoo HS, Ko JH, Kim JM, Choi JY, Kim IG, Paik SG, Cho EW (2010) Identification of autoantibody against fatty acid synthase in hepatocellular carcinoma mouse model and its application to diagnosis of HCC. Int J Oncol 36(6):1453-1459
46. Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M (2009) Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 378(2):279-284. doi:10.1016/j.bbrc.2008.11.033
47. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6(11):836-848. doi:10.1038/nri1961
48. Smyth MJ, Crowe NY, Godfrey DI (2001) NK cells and NKT cells collaborate in host protection from methylcholanthreneinduced fibrosarcoma. Int Immunol 13(4):459-463
49. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148. doi:10.1016/j.immuni.2004.07.017
50. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H (1999) The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 30(2):413-421. doi:10.1002/hep.510300237
51. Nagao M, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu Y, Ko S, Tatekawa Y, Ikeda N, Kanokogi H, Urizono Y, Kobayashi T, Shibaji T, Kanamura T, Ogawa S, Nakano H (2000) The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology 32(3):491-500. doi:10.1053/jhep.2000.16470
52. Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A (2009) Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137(2):682-690. doi:10.1053/j.gastro.2009.04.045
53. Hsu PN, Yang TC, Kao JT, Cheng KS, Lee YJ, Wang YM, Hsieh CT, Lin CW, Wu YY (2010) Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma. Liver Int 30(9):1379-1386. doi:10.1111/j.1478-3231.2010.02323.x
54. Maki A, Matsuda M, Asakawa M, Kono H, Fujii H, Matsumoto Y (2004) Decreased expression of CD28 coincides with the downmodulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients. J Gastroenterol Hepatol 19(12):1348-1356. doi:10.1111/j.1440-1746.2004.03455.x
55. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128 (4):887-896. doi:10.1002/ijc.25397
56. Wu K, Kryczek I, Chen L, Zou W, Welling TH (2009) Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 69(20):8067-8075. doi:10.1158/0008-5472.CAN-09-0901
57. Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M, Lehner F, Manns MP, Korangy F, Greten TF (2006) Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 12(20):3275-3282
58. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65(6):2457-2464. doi:10.1158/0008-5472.CAN-04-3232
59. Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y (2006) Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45(2):254-262. doi:10.1016/j.jhep.2006.01.036
60. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ (2005) Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41(4):722-730. doi:10.1002/hep.20644
61. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS (2007) Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132(7):2328-2339. doi:10.1053/j.gastro. 2007.03.102
62. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S (2007) FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13(3):902-911. doi:10.1158/1078-0432.CCR-06-2363
63. Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson DR (2007) Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+) CD25 (+) regulatory T cells. Lab Invest 87 (6):582-590. doi:10.1038/labinvest.3700540
64. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L (2009) Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 125(7):1640-1648. doi:10.1002/ijc.24556
65. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, Korangy F (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+) CD25 (+) Foxp3 (+) T cells. Gastroenterology 135 (1):234-243. doi:10.1053/j.gastro.2008.03.020
66. Chu MH, Chien SC, Hu CP, Wang CY, Lee SD, Tsai YT, Wu JC, Han SH, Chang CM (1988) Natural and activated cytotoxic lymphocytes reactivity to human hepatocellular carcinoma cell lines in hepatocellular carcinoma patients. Liver 8(4):198-207
67. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, Zhang H, Yang Y, Wu H, Tien P, Wang FS (2008) Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 129(3):428-437. doi:10.1016/j.clim.2008.08.012
68. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N (2005) Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43(6):1013-1020. doi:10.1016/j.jhep.2005. 05.026
69. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50(3):799-807. doi:10.1002/hep. 23054
70. Witkowski M, Spangenberg HC, Neumann-Haefelin C, Buttner N, Breous E, Kersting N, Drognitz O, Hopt UT, Blum HE, Semmo N, Thimme R (2010) Lack of ex vivo peripheral and intrahepatic alpha-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int J Cancer. doi:10.1002/ijc.25866
71. Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, Makowiec F, Obermaier R, Hopt UT, Blum HE, Spangenberg HC (2008) Comprehensive analysis of the alphafetoproteinspecific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology 48(6):1821-1833. doi:10.1002/hep.22535
72. Behboudi S, Alisa A, Boswell S, Anastassiou J, Pathan AA, Williams R (2010) Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease. Br J Cancer 102(4):748-753. doi:10.1038/sj.bjc.6605526
73. Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M (2007) Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 141(2):196-202. doi:10.1016/j.surg.2006.06.033
74. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232):802-807. doi:10.1016/S0140- 6736(00)02654-4
75. Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C, Missale G (2010) Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 138(5):1931-1942. doi:10.1053/j.gastro.2009.12.051
76. Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, Schivazappa S, Laccabue D, Cavallo C, Schianchi C, Ferrari C, Missale G (2008) Increased immunostimulatory activity conferred to antigenpresenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother 31(3):271-282. doi:10.1097/CJI.0b013e318160ff1c
77. Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, Meckel S, Eisele S, Encke J, Blum HE, Geissler M (2000) Mouse alphafetoproteinspecific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119(4):1104-1112
78. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS (2006) A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12(9):2817-2825. doi:10.1158/1078-0432.CCR-05-2856
79. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, Adams DH (2009) A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49(1):124-132. doi:10.1002/hep.22626
80. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptidevaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97(22):12198-12203. doi:10.1073/pnas.220413497220413497
81. Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y (2003) NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer 106(2):236-243. doi:10.1002/ijc.11201
82. Margalit M, Shibolet O, Klein A, Elinav E, Alper R, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y (2005) Suppression of hepatocellular carcinoma by transplantation of ex-vivo immunemodulated NKT lymphocytes. Int J Cancer 115(3):443-449. doi:10.1002/ijc.20889